TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Instagram Outage Disrupts Thousands of U.S. Users 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Heidelberg, Germany, May 11, 2016 -- Affimed N.V. (Nasdaq:AFMD) today announced that on May 18, 2016, the Company will release its financial results for the quarter ended March 31, 2016. The Company's management team will host a conference call to discuss the Company's financial results and recent corporate developments on Wednesday, May 18, 2016 at 8:30 a.m. EST. The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code 5430699.
| Local - Amsterdam, the Netherlands: | +31 (0) 20 721 9157 |
| Local - Copenhagen, Denmark: | +4532 71 1665 |
| Local – Frankfurt, Germany: | +49 (0) 69 2222 10644 |
| Local - Geneva, Switzerland: | +41 (0) 22 567 5429 |
| Local - London, U.K.: | +44 (0) 20 3427 1930 |
| Local - New York City, U.S.A.: | +1 646 254 3369 |
| Local - Paris, France: | +33 (0) 1 70 48 01 63 |
An audio webcast of the conference call can be accessed in the "Events" section on the "Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the webcast will be available on Affimed's website shortly after the conclusion of the call and will be archived on the Affimed website for 30 days following the call.
About Affimed N.V.
Affimed (Nasdaq:AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
CONTACT: IR Contact:
Caroline Stewart, Head IR
Phone: +1 347394 6793
E-Mail: [email protected] or [email protected]
Media Contact:
Anca Alexandru, Head of Communications
Phone: +49 6221 64793341
E-Mail: [email protected]
